Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (OP: CMNDF ) N/A UNCHANGED Last Price Updated: 10:24 AM EST, Nov 11, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 7.900 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split November 15, 2022 Psychedelics biotech firm Clearmind Medicine Inc. Via Benzinga Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market November 14, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Performance More News Read More Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV October 11, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements September 26, 2022 Via Benzinga SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc. June 07, 2022 Via Benzinga SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes September 22, 2022 Via Benzinga Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration August 25, 2022 Via Benzinga SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. August 25, 2022 Via Benzinga Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know August 24, 2022 Via Benzinga Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies June 08, 2022 Via Benzinga The Bad And The Ugly? The State Of Excessive Alcohol Consumption In The U.S. June 08, 2022 Via Benzinga Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics June 07, 2022 Via FinancialNewsMedia Exposures COVID-19 SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction June 02, 2022 Via Benzinga SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction June 02, 2022 Via Benzinga New Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine June 01, 2022 Via Benzinga High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA May 26, 2022 Via Benzinga Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company May 24, 2022 Via Benzinga Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results May 24, 2022 Via Benzinga Global Psychedelics Market Is Expected To Reach $8 Billion By 2029 May 24, 2022 Via FinancialNewsMedia Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End May 19, 2022 Via Benzinga Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies May 17, 2022 Via Benzinga Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested May 13, 2022 Via Benzinga SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application May 11, 2022 Via Benzinga SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors May 10, 2022 Via Benzinga Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice March 17, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.